Comparison of the effects of aflibercept and dexamethasone in central retinal vein occlusion with serous retinal detachment

ABSTRACT Clinical relevance Previous studies have shown the efficacy of aflibercept and dexamethasone in central retinal vein occlusion. However, the efficacy of these two drugs in central retinal vein occlusion accompanied by serous macular detachment has not been investigated and compared. This results in a search for more precise data to evaluate the effects of two drugs in real-world studies. Background The aim of this study is to compare the efficacy of intravitreal aflibercept and dexamethasone implantation injections in central retinal vein occlusion accompanied by serous retinal detachment. Methods Sixty-eight eyes of 68 patients with treatment-naive macular oedema post-central retinal vein occlusion were enrolled in the retrospectively designed study. All of the patients had serous retinal detachment at baseline. The patients received three intravitreal aflibercept injections with an interval of four weeks and followed by pro re nata treatment protocol (intravitreal aflibercept group, n = 37) or a single dose dexamethasone implantation injection (dexamethasone implantation group, n = 31). Best-corrected visual acuity, central retinal thickness and the height of serous retinal detachment parameters were compared at baseline, and in the first, second, third and sixth months. Results The groups were similar in terms of baseline characteristics (p > 0.05 for all). The visual gain was greater in the intravitreal aflibercept group (p = 0.013). While the intravitreal aflibercept group had a significant central retinal thickness decrease in the first and sixth months (p = 0.011 and p = 0.001, respectively), this superiority was not observed during the entire follow-up period (p = 0.212). There was no difference in serous retinal detachment resolution between the groups (p = 0.403). Two patients in the intravitreal aflibercept group (5.4%) and five patients in the dexamethasone implantation group (16.1%) had serous retinal detachment at the final visit (p = 0.158). Conclusion Both intravitreal aflibercept and dexamethasone implantation injections seemed to be effective in the treatment of central retinal vein occlusion with serous retinal detachment. Intravitreal aflibercept treatment yielded better results in terms of visual gain and showed a faster anatomical response.

[1]  B. Erden,et al.  Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema , 2019, Cutaneous and ocular toxicology.

[2]  A. Kvanta,et al.  INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial. , 2019, Retina.

[3]  E. Doğan,et al.  Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion , 2018, Clinical ophthalmology.

[4]  H. Kaldırım,et al.  A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion , 2018, International Ophthalmology.

[5]  S. Vujosevic,et al.  Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional Entities. , 2017, American journal of ophthalmology.

[6]  U. Schmidt-Erfurth,et al.  Effect of intravitreal dexamethasone implant on intra‐ocular cytokines and chemokines in eyes with retinal vein occlusion , 2017, Acta ophthalmologica.

[7]  H. Ozdemir,et al.  Intravitreal Dexamethasone Implant for Treatment of Serous Macular Detachment in Central Retinal Vein Occlusion. , 2017, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[8]  F. Pichi,et al.  Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion , 2017, International Ophthalmology.

[9]  D. Călugăru,et al.  Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  P. Campochiaro,et al.  Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. , 2016, Ophthalmology.

[11]  Gerard Reid,et al.  OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS , 2015, Retina.

[12]  D. Papaconstantinou,et al.  Safety and efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors. , 2015, Current Drug Safety.

[13]  F. Holz,et al.  Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion , 2014, Ophthalmologica.

[14]  T. Yamashita,et al.  RETINAL MORPHOLOGIC CHANGES AND CONCENTRATIONS OF CYTOKINES IN EYES WITH DIABETIC MACULAR EDEMA , 2014, Retina.

[15]  J. Glanville,et al.  Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review , 2014, BMC Ophthalmology.

[16]  U. Schmidt-Erfurth,et al.  Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. , 2014, Ophthalmology.

[17]  S. Sivaprasad,et al.  Differences in the topographic profiles of retinal thickening in eyes with and without serous macular detachment associated with diabetic macular oedema , 2013, British Journal of Ophthalmology.

[18]  P. Mitchell,et al.  Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. , 2012, Ophthalmology.

[19]  Min Zhao,et al.  Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. , 2011, Investigative ophthalmology & visual science.

[20]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[21]  A. Tsujikawa,et al.  Serous retinal detachment associated with retinal vein occlusion. , 2010, American journal of ophthalmology.

[22]  K. Bartz-Schmidt,et al.  Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[23]  S. Kishi,et al.  Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. , 2009, American journal of ophthalmology.

[24]  H. Ozdemir,et al.  SEROUS MACULAR DETACHMENT IN CENTRAL RETINAL VEIN OCCLUSION , 2005, Retina.

[25]  R. Klein,et al.  The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. , 2000, Transactions of the American Ophthalmological Society.

[26]  M. Battaglia Parodi,et al.  Branch retinal vein occlusion and exudative retinal detachment: pathogenetical aspects. , 1994, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.